Analyst Price Targets — PLRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 12, 2026 1:20 pm | Yasmeen Rahimi | Piper Sandler | $3.00 | $1.37 | StreetInsider | Pliant Therapeutics (PLRX) PT Lowered to $3 at Piper Sandler |
| March 3, 2025 7:24 pm | — | Stifel Nicolaus | $3.00 | $1.38 | TheFly | Pliant Therapeutics downgraded to Hold from Buy at Stifel |
| March 3, 2025 5:25 pm | — | Leerink Partners | $2.00 | $1.38 | TheFly | Pliant Therapeutics downgraded to Market Perform from Outperform at Leerink |
| September 13, 2024 6:43 am | Ed Arce | H.C. Wainwright | $38.00 | $11.84 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Pliant Therapeutics (PLRX) |
| September 9, 2024 6:28 am | Faisal Khurshid | Leerink Partners | $33.00 | $12.87 | TheFly | Pliant Therapeutics assumed with an Outperform at Leerink |
| May 23, 2024 8:44 am | Yasmeen Rahimi | Piper Sandler | $40.00 | $13.85 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Pliant Therapeutics (PLRX) |
| May 7, 2024 8:29 am | Alex Thompson | Stifel Nicolaus | $32.00 | $13.91 | StreetInsider | Pliant Therapeutics (PLRX) PT Lowered to $32 at Stifel |
| May 7, 2024 7:42 am | Jeff Jones | Oppenheimer | $48.00 | $13.79 | StreetInsider | Pliant Therapeutics (PLRX) PT Raised to $48 at Oppenheimer |
| May 7, 2024 7:09 am | Ed Arce | H.C. Wainwright | $36.00 | $13.79 | StreetInsider | Pliant Therapeutics (PLRX) PT Lowered to $36 at H.C. Wainwright |
| May 7, 2024 6:19 am | Brian Abrahams | RBC Capital | $45.00 | $13.79 | StreetInsider | Pliant Therapeutics (PLRX) PT Lowered to $45 at RBC Capital |
Latest News for PLRX
Connor Clark and Lunn Investment Management Ltd. bought a new stake in Pliant Therapeutics, Inc. (NASDAQ: PLRX) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 536,081 shares of the company's stock, valued at approximately $611,000. Connor Clark and Lunn Investment Management
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, in combination with pembrolizumab for the potential the treatment of solid tumors that are resistant to immune…
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, experiencing strong enrollment Appointed seasoned oncology drug development leaders Flavia Borellini, Ph.D. and Robert Iannone, M.D.
Appointments bring global oncology drug development experience and deepen Board's operational and regulatory expertise
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PLRX.
U.S. House Trading
No House trades found for PLRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.